Michelle Louise Thom

Michelle Louise Thom

The Pirbright Institute, Woking, Surrey, UK
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2004 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
JHJayne Hope
Jayne Hope
MTMichelle Louise Thom
Michelle Louise Thom
BVB. Villarreal‐Ramos
B. Villarreal‐Ramos
HVH. M. Vordermeier
H. M. Vordermeier
RHR. G. Hewinson
R. G. Hewinson
CHC. J. Howard
C. J. Howard

1 March 2002 in Veterinary Immunology and Immunopathology
Verified
Journal Article
Closed access
LKL.S. Kwong
L.S. Kwong
JHJayne Hope
Jayne Hope
MTMichelle Louise Thom
Michelle Louise Thom
PSP. Sopp
P. Sopp
SDS. Duggan
S. Duggan
CHC.J. Howard
C.J. Howard

1 July 2005 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
JHJayne Hope
Jayne Hope
MTMichelle Louise Thom
Michelle Louise Thom
BVB. Villarreal‐Ramos
B. Villarreal‐Ramos
HVH. M. Vordermeier
H. M. Vordermeier
RHR. G. Hewinson
R. G. Hewinson
CHC. J. Howard
C. J. Howard

17 March 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GCG. Stuart Cockerill
G. Stuart Cockerill
RARichard M. Angell
Richard M. Angell
ABAlexandre Bedernjak
Alexandre Bedernjak
ICIrina Chuckowree
Irina Chuckowree
IFIan Fraser
Ian Fraser
KPKenneth Powell
Kenneth Powell

12 August 2015 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
GTGeraldine Taylor
Geraldine Taylor
MTMichelle Louise Thom
Michelle Louise Thom
SCStefania Capone
Stefania Capone
APAngiolo Pierantoni
Angiolo Pierantoni
EGEfrain Guzman
Efrain Guzman
AVAlessandra Vitelli
Alessandra Vitelli
A vectored human RSV vaccine protects young seronegative calves.

20 June 2012 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
MTMichelle Louise Thom
Michelle Louise Thom
MMM. McAulay
M. McAulay
HVH. M. Vordermeier
H. M. Vordermeier
DCD. Clifford
D. Clifford
RHR. G. Hewinson
R. G. Hewinson
JHJayne Hope
Jayne Hope
Vaccination of neonatal calves withMycobacterium bovisbacillus Calmette-Guérin (BCG) induces a significant degree of protection against bovine tuberculosis, caused by infection with virulentM. bovis. In two independent experiments, we assessed the duration of the protective immunity induced in calves by neonatal vaccination with BCG Danish. Protection from disease was assessed at 12 and 24 months postvaccination in cattle challenged via the endotracheal route withM. bovis. We also assessed antigen-specific immune responses to assess their utility as correlates of protection. At 12 months postvaccination, significant reductions in lung and lymph node pathologies were observed compared to nonvaccinatedM. bovis-challenged control cattle. At 24 months post-BCG vaccination, there was a reduction in lung and lymph node pathology scores and in bacterial burden. However, when comparing vaccinated and control groups, this did not reach statistical significance. Vaccination induced long-lived antigen (purified protein derivative [PPD])-specific gamma interferon (IFN-γ) release in whole-blood cultures, which remained above baseline levels for more than 20 months (approximately 90 weeks). The number of antigen-specific IFN-γ-secreting central memory T cells present at the time ofM. bovischallenge was significantly higher in vaccinated than in control animals at 12 months postvaccination, but not at 24 months. Vaccination of neonatal calves with BCG Danish induced protective immune responses against bovine TB which were maintained for at least 12 months postvaccination. These studies provide data on the immunity induced by BCG vaccination in calves; the results could inform vaccination strategies for the control of bovine TB in United Kingdom cattle herds.